Show simple item record

dc.creatorMedhat, Arvin
dc.creatorArzumanyan, Alla
dc.creatorFeitelson, Mark A.
dc.date.accessioned2021-10-05T19:38:51Z
dc.date.available2021-10-05T19:38:51Z
dc.date.issued2021-09-04
dc.identifier.citationMedhat A., Arzumanyan A., Feitelson M. A. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget. 2021; 12. Retrieved from https://www.oncotarget.com/article/28077/
dc.identifier.issn1949-2553
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/6941
dc.identifier.urihttp://hdl.handle.net/20.500.12613/6960
dc.description.abstractHepatitis B virus (HBV) is a human pathogen that has infected an estimated two billion people worldwide. Despite the availability of highly efficacious vaccines, universal screening of the blood supply for virus, and potent direct acting anti-viral drugs, there are more than 250 million carriers of HBV who are at risk for the sequential development of hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). More than 800,000 deaths per year are attributed to chronic hepatitis B. Many different therapeutic approaches have been developed to block virus replication, and although effective, none are curative. These treatments have little or no impact upon the portions of integrated HBV DNA, which often encode the virus regulatory protein, HBx. Although given little attention, HBx is an important therapeutic target because it contributes importantly to (a) HBV replication, (b) in protecting infected cells from immune mediated destruction during chronic infection, and (c) in the development of HCC. Thus, the development of therapies targeting HBx, combined with other established therapies, will provide a functional cure that will target virus replication and further reduce or eliminate both the morbidity and mortality associated with chronic liver disease and HCC. Simultaneous targeting of all these characteristics underscores the importance of developing therapies against HBx.
dc.format.extent13 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartOncotarget
dc.relation.isreferencedbyImpact Journals
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/
dc.subjectChronic liver disease
dc.subjectHepatocellular carcinoma
dc.subjectHBx
dc.subjectFunctional cure
dc.subjectEpigenetic
dc.titleHepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma
dc.typeText
dc.type.genreJournal article
dc.description.departmentBiology
dc.relation.doihttps://doi.org/10.18632/oncotarget.28077
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.temple.creatorArzumanyan, Alla
dc.temple.creatorFeitelson, Mark A.
refterms.dateFOA2021-10-05T19:38:51Z


Files in this item

Thumbnail
Name:
Feitelson-JournalArticle-2021- ...
Size:
1.377Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY